Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Congress Scientific Watch

The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.

Login and start reading, or Join ESMO - All articles are Open Access after 6 months.

Filter by:

68 results

Breast Cancer;  Personalised/Precision Medicine

Neoadjuvant T-DXd Shows Promise For Localised HER2-Low Breast Cancer

From San Antonio Breast Cancer Symposium 2022:
The phase II TRIO-US B-12 TALENT clinical trial has shown that people with hormone-receptor-positive, HER2-low localised breast cancer may benefit from neoadjuvant trastuzumab deruxtecan

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.